Updated:
Novotech
Novotech was founded in 1997 in Australia by a team of clinical research professionals, starting with a regulatory affairs focus and expanding organically...
Novotech
Novotech was founded in 1997 in Australia by a team of clinical research professionals, starting with a regulatory affairs focus and expanding organically into a global full-service CRO. The company moved its headquarters to Singapore and is now owned by a consortium including TPG, GIC, and Temasek, reflecting the scale of its operations. The firm provides end-to-end clinical trial services — from early-phase and first-in-human studies through late-stage trials, regulatory consulting, biometrics, laboratory services, and real-world data analysis. Its therapeutic specialties include oncology, liver disease, infectious diseases and vaccines, orphan and rare diseases, and radiopharmaceuticals. Novotech has completed 4,450+ trials and contributed to 60+ drugs reaching market. Key acquisitions include EastHORN (Europe), NCGS (US), CBR International (US), and CNS-focused CROs, along with stakes in ObvioHealth and Prospection. The company operates from over 30 offices spanning Asia-Pacific, Europe, North America, Africa, and the Middle East. With a team of experienced clinical operations and regulatory professionals, Novotech also manages the Acrostar SMO site management division and a bioanalytical laboratory network. Its FLEX platform offers flexible cost and capacity models for biotech clients. Novotech's structure as a PE-backed, independent CRO with strong Asia-Pacific roots differentiates it from competitors headquartered in North America or Western Europe. Its ownership by sovereign wealth funds (GIC, Temasek) and TPG provides deep capital for continued global expansion and capability building.
General information
Firm type
Asset Manager
Year founded
1997
AUM
Undisclosed
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
Singapore, Singapore
Additional offices
Sydney, Australia · Warsaw, Poland · Bucharest, Romania · Boulder, United States · San Francisco, United States · Shanghai, China · Beijing, China · Seoul, South Korea · Bangalore, India · Cologne, Germany · Madrid, Spain · London, UK (implied by Europe offices)
Sector focus
Frequently asked questions
Who owns Novotech?
Novotech is owned by a consortium of investors led by TPG, which acquired a controlling stake in the company, along with GIC and Temasek, two major Singapore sovereign wealth funds. These investors supported the merger of Novotech Group and PPC Group to form Novotech Health Holdings.
What clinical trial phases does Novotech cover?
Novotech covers all phases of clinical development, from first-in-human and early-phase studies through to Phase III and regulatory submission. The company has particular expertise in early-phase oncology and rare disease studies conducted in Australia, where regulatory pathways are faster.
In which therapeutic areas does Novotech specialize?
Novotech's stated therapeutic specializations include oncology, liver disease, infectious diseases and vaccines, orphan and rare diseases, and radiopharmaceuticals. It also offers services across general medicine through its broad CRO operations.
Does Novotech operate only in Asia-Pacific?
No. Novotech operates across more than 30 office locations in Asia-Pacific, Europe, North America, Africa, and the Middle East. Its global footprint includes offices in the US, Poland, Germany, Spain, India, South Korea, China, and Australia, among others.
What is Novotech's relationship with Acrostar?
Acrostar is Novotech's Site Management Organization (SMO) division. It operates as a dedicated entity providing clinical trial site management services, complementing Novotech's broader CRO offerings.
How does Novotech differentiate from other large CROs?
Novotech positions itself as an Asia-Pacific-originated global CRO with deep regional expertise, particularly in Australia's fast early-phase regulatory environment. Its ownership by TPG, GIC, and Temasek provides strategic capital for acquisitions and expansion, setting it apart from publicly traded or private-equity-only competitors.
What recent acquisitions has Novotech made?
Notable acquisitions include EastHORN (Europe), NCGS (US), and CBR International (US). Novotech also took minority stakes in ObvioHealth (decentralized clinical trials) and Prospection (health analytics). The company merged with PPC Group to form Novotech Health Holdings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: